Lantern Pharma Q2 FY26 operating loss narrows 25% to $3.5 million; net loss widens to $7.1 million - LTRN News | RalliesLantern Pharma Q2 FY26 operating loss narrows 25% to $3.5 million; net loss widens to $7.1 million
L
LTRN• Program update
- Lantern formed Open Medicine AI as a separate company; LP-300 HARMONIC data showed 8.9-month median PFS in L858R patients completing six cycles.
Q2 results and cost trends
- Lantern Pharma posted a Q2 2026 net loss of $7.1 million, or $0.57 per share, widening from $4.3 million.
- Operating loss narrowed 25% year over year to about $3.5 million, while cash and marketable securities totaled about $7.4 million.
- R&D expense fell 42% to about $1.8 million; G&A expense rose 8% to about $1.7 million.
- Warrant expense totaled about $3.6 million, driven mainly by a higher fair value tied to a stock-price increase.
GALT
•
